AB Science S.A. (ABSCF)
| Previous close | 7.25 |
| Open | 7.25 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 7.25 - 7.25 |
| 52-week range | 7.25 - 16.10 |
| Volume | |
| Avg. volume | 7 |
| Market cap | 342.553M |
| Beta (5Y monthly) | 0.98 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.25 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Globe Newswire
AB Science - Positive recommendation of the Data and Safety Monitoring Board to continue the Phase 2 study evaluating the antiviral activity of masitinib in Covid-19
PRESS RELEASE POSITIVE RECOMMENDATION OF THE DATA AND SAFETY MONITORING BOARD TO CONTINUE THE PHASE 2 STUDY EVALUATING ANTIVIRAL ACTIVITY OF MASITINIB IN COVID-19 Paris, 14 September 2022, 6.15pm CET AB Science SA (Euronext - FR0010557264 - AB) today announced continuation of the Phase 2 study evaluating the antiviral activity of masitinib in patients who have a confirmed diagnosis of COVID-19, following the recommendation of the Data and Safety Monitoring Board (DSMB). This randomized (1:1), do
- Globe Newswire
AB Science announces that it has filed an application for conditional Marketing Authorization to EMA for masitinib in the treatment of ALS
PRESS RELEASE AB SCIENCE ANNOUNCES FILING OF MARKETING AUTHORIZATION APPLICATION FOR ALSITEK IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) AND ITS VALIDATION BY THE EUROPEAN MEDICINES AGENCY (EMA) Paris, 24 August 2022, 7pm CET AB Science SA (Euronext - FR0010557264 - AB) today announced that it has filed an application for conditional Marketing Authorization to the European Medicines Agency (EMA) for Alsitek (masitinib) in the treatment of amyotrophic lateral sclerosis (ALS). This app
- Globe Newswire
AB Science today announced publication of results from its positive study of masitinib in severe asthma uncontrolled by oral corticosteroids in the peer-reviewed Journal of Asthma and Allergy
PRESS RELEASE AB SCIENCE ANNOUNCES PUBLICATION IN THE JOURNAL OF ASTHMA AND ALLERGY OF POSITIVE MASITINIB PHASE 3 CLINICAL TRIAL RESULTS IN PATIENTS WITH ORAL CORTICOSTEROID-DEPENDENT SEVERE ASTHMA Paris, 7 June, 2022, 5.45pm CET AB Science SA (Euronext - FR0010557264 - AB) today announced publication of results from its positive study of masitinib in severe asthma uncontrolled by oral corticosteroids (OCS) in the peer-reviewed Journal of Asthma and Allergy [1]. This article, titled ‘Efficacy an
